How many insider trades does FilingIQ track for OCUL?

FilingIQ tracks 251 Form 4 insider transactions for OCUL (OCULAR THERAPEUTIX, INC), covering filings from Jun 10, 2015 onwards. 8 of those were filed in the last 90 days.

Are OCUL insiders net buyers or net sellers?

Across the full Form 4 history for OCUL, 66 transactions (26%) were open-market purchases and 73 (29%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does OCUL insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is OCUL in?

OCULAR THERAPEUTIX, INC (OCUL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.89B.

OCUL insider trading

NasdaqGM Healthcare

OCULAR THERAPEUTIX, INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

251

Last 90 days

Buys / sells

26% / 29%

Market cap

$1.89B

About OCULAR THERAPEUTIX, INC

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Company website: www.ocutx.com

OCUL insider activity at a glance

FilingIQ has scored 251 insider transactions for OCUL since Jun 10, 2015. The most recent filing in our index is dated Apr 9, 2026.

Across the full history, 66 open-market purchases and 73 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on OCUL insider trades is 54.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live OCUL trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding OCUL

Avoro Capital Advisors LLC

$130.84M · 1.3% of AUM

Logos Global Management LP

$35.23M · 2.8% of AUM

Opaleye Management Inc.

$19.36M · 2.6% of AUM

Frequently asked

How many insider trades does FilingIQ track for OCUL?: FilingIQ tracks 251 Form 4 insider transactions for OCUL (OCULAR THERAPEUTIX, INC), covering filings from Jun 10, 2015 onwards. 8 of those were filed in the last 90 days.
Are OCUL insiders net buyers or net sellers?: Across the full Form 4 history for OCUL, 66 transactions (26%) were open-market purchases and 73 (29%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does OCUL insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is OCUL in?: OCULAR THERAPEUTIX, INC (OCUL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.89B.

Methodology & sources

Every OCUL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.